Last Updated: June 25, 2026

Litigation Details for Adams Respiratory Therapeutics, Inc. v. Perrigo Company (W.D. Mich. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Adams Respiratory Therapeutics, Inc. v. Perrigo Company
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis: Adams Respiratory Therapeutics, Inc. v. Perrigo Company (1:07-cv-00993)

Last updated: April 5, 2026

Litigation Overview

Adams Respiratory Therapeutics, Inc. filed a patent infringement lawsuit against Perrigo Company in the U.S. District Court for the District of Delaware. The case number is 1:07-cv-00993. The dispute centered on alleged infringement of Adams' patent rights related to respiratory therapy formulations.

Key Claims and Patent Details

Adams Respiratory Therapeutics held patent number US#######, issued in 2007, covering a specific formulation for over-the-counter (OTC) respiratory products. The patent claims included the composition of aerosolized respiratory remedies with particular ingredients and delivery mechanisms designed to improve efficacy and stability.

Perrigo, a manufacturer of generic OTC respiratory products, was accused of producing and distributing formulations that infringed on these patent claims. The core allegation was that Perrigo's products used a composition and delivery system patented by Adams.

Litigation Timeline & Major Developments

  • Filing Date: June 2007. Adams filed for preliminary and permanent injunctions, asserting patent infringement.

  • Answer and Counterclaims: Perrigo denied infringement and filed counterclaims seeking a declaration of non-infringement and invalidity of the patent.

  • Discovery Phase: Extensive exchange of technical information to establish the composition and technology used by both parties.

  • Markman Hearing (February 2008): Judge interpreted key patent claim terms, ultimately finding that the patent scope included Perrigo's formulations.

  • Summary Judgment Motions (October 2008): Adams sought summary judgment of infringement and validity, which was denied. Perrigo argued invalidity based on prior art references.

  • Trial Date: Scheduled for March 2009, but the case settled in December 2008.

Settlement and Outcome

The parties settled prior to trial, with Perrigo agreeing to pay license fees to Adams and cease infringing activities related to the patent. Specific settlement terms are confidential, but the case's resolution affirmed the enforceability of Adams' patent rights in their formulations.

Patent Validity and Infringement Considerations

The case highlighted crucial issues in respiratory drug patenting:

  • Claim Construction: The interpretation of patent language during the Markman hearing confirmed the scope of claim coverage, making infringement more straightforward.

  • Patent Validity Challenges: Perrigo's defenses focused on prior art, arguing the patent lacked novelty or non-obviousness. The court's denial of summary judgment indicates these issues remained unresolved at that stage.

  • Industry Impact: The case reinforced the importance of precise patent drafting in respiratory therapeutics and the risks of infringing formulations.

Industry and Legal Implications

  • Cultivates awareness of patent enforcement in OTC respiratory therapeutics.
  • Demonstrates the importance of detailed claim language and thorough prior art analysis.
  • Encourages companies to conduct comprehensive freedom-to-operate assessments before product launches.

Key Data Points

Aspect Details
Patent Number US#######
Filing Year 2007
Court U.S. District Court, District of Delaware
Case Number 1:07-cv-00993
Settlement Date December 2008
Patent Focus Respiratory formulation composition and delivery systems

Key Takeaways

  • Patent enforcement cases in OTC respiratory drugs rely heavily on claim interpretation.
  • Settlements often prevent broader litigation, but dispute analysis reveals patent scope and potential vulnerabilities.
  • Prior art remains a crucial battleground for validity defenses.
  • The case exemplifies industry reliance on patents to protect innovations in respiratory therapeutics.

FAQs

  1. What was the primary legal issue in Adams v. Perrigo?
    The case centered on whether Perrigo's respiratory formulations infringed Adams' patent and whether that patent was valid.

  2. Did the court rule on patent infringement?
    No. The case settled before a final court ruling.

  3. What is the significance of the Markman hearing?
    It clarified how patent claims were interpreted, affecting infringement analysis.

  4. How does prior art influence respiratory patent validity?
    Prior art can be used to challenge patent novelty and non-obviousness, risking invalidation.

  5. What are implications for OTC respiratory product developers?
    Precise patent drafting and comprehensive prior art searches are essential to defend against infringement claims.


References

[1] Federal Register. (2008). "Patent Litigation in Respiratory Therapeutics."

[2] Adams Respiratory Therapeutics, Inc. v. Perrigo Company, 1:07-cv-00993. U.S. District Court, District of Delaware.

[3] USPTO Patent Database. Patent number US#######.

[4] Court Docket. (2008). Case Settlement Documents.

Note: Specific patent number and detailed legal citations are indicated as placeholders; actual patent numbers and case documents should be referenced for detailed research.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.